ContextMedia:Health, the leading provider of digital solutions at the point of care, today announced the launch of a content development partnership with the Heart Rhythm Society (HRS), the country's leading resource on heart rhythm disorders. The partnership will bring content from the HRS educational library to patients in ContextMedia:Health's network of 25,000 practices by way of ContextMedia:Health's suite of digital waiting room and exam room platforms.
Showing all archived press releases starting with 2016. Back
The mid to long-term results from the EFFORTLESS study, the largest subcutaneous implantable cardioverter-defibrillator (S-ICD) registry in the world, show the device provides reliable treatment for ventricular tachyarrhythmias. This is the first report on the fully enrolled EFFORTLESS cohort and includes real-world outcomes of almost 1,000 patients implanted with an S-ICD. Positive results showing longevity during three- and up to five-year follow-ups were presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.
A new study shows the use of novel anticoagulants (such as rivoraxiban, apixiban and dabigatran) to treat atrial fibrillation (AF) on an “as needed basis” guided by diligent pulse monitoring can be an effective and safe way to lower overall risk of stroke. The study includes motivated patients that were eager to seek an alternative to long-term, daily oral anticoagulation therapy (OAT) after ablation or drug therapy. The research was presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.
The Heart Rhythm Society (HRS), in partnership with Boehringer Ingelheim Pharmaceuticals, Inc., announced today that Mark H. Eckman, MD, University of Cincinnati, Cincinnati, and Steven A. Lubitz, MD, MPH, Massachusetts General Hospital, Boston, were awarded the Atrial Fibrillation (AFib) Quality Improvement (QI) Innovation Grant. The grant support will help innovation and advancement in atrial fibrillation and stroke prevention through research aimed at addressing National QI priorities. Dr. Eckman won for his proposal on Shared Decision-Making Tool for Thromboprophylaxis in Atrial Fibrillation and Dr. Lubitz won for his proposal on Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation. They presented to an expert panel during Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.
A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that receive long-term, blood thinner, warfarin (Coumadin) compared to patients that use warfarin for conditions other than AF. The study of more than 10,000 patients treated with warfarin long-term found that patients with AF experience higher rates of dementia, Alzheimer’s disease and vascular dementia compared to anticoagulated non-AF patients. The research was presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.
The first ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in cardiac resynchronization therapy (CRT) patients. Early performance results from the Clinical Response to Cardiac Resynchronization Therapy with the SonR Hemodynamic Sensor: The RESPOND-CRT Randomized Trial were presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions and show reduction in hospitalizations for this patient population by 35 percent.
A new, large study shows that 95.7 percent of individual leads were successfully removed using a procedure called transvenous lead extraction (TLE). The ELECTRa (European Lead Extraction ContTRolled) Registry, hosted by the European Heart Rhythm Association (EHRA) a registered branch of the European Society of Cardiology (ESC), is the first multinational, multi-center, prospective registry of consecutive patients undergoing TLE. The research was presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions, and includes data from both high volume and low volume medical centers.
A new study presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions, found that among patients with heart failure, atrial fibrillation (AF) was significantly less common among African Americans and Hispanics than among non-Hispanic Whites. This study indicates a strong correlation between race and ethnicity and the development of AF for patients with heart failure.
Results from a first-of-its-kind study identify a significant increase in the incidence of atrial fibrillation (AF) among patients with pacemaker-detected sleep apnea. The study, presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions, suggests that monitoring for sleep apnea in patients with pacemakers is imperative in identifying patients’ risk for developing AF.
Heart Rhythm 2016, the Heart Rhythm Society’s (HRS) 37th Annual Scientific Sessions and this year’s leading conference on cardiac arrhythmias, commences at the Moscone Center. The meeting focuses on the importance of collaboration to propel the field of cardiac pacing and electrophysiology (EP) forward. HRS is the only organization that brings together the world’s leading clinicians, scientists and allied health professionals to help end death and suffering from heart rhythm disorders.